The controversy surrounding Dr. Mehmet Oz’s folinic acid sales reflects more than just interest in supplements; it also shows how medical policy and celebrity credibility clash. Leucovorin, the FDA-approved prescription equivalent of folinic acid, a form of vitamin B9 that has long been used in oncology, has garnered renewed attention for children with autism who exhibit cerebral folate deficiency. With Oz standing next to President Trump and Secretary Robert F. Kennedy Jr., the announcement instantly set off a flurry of conjecture.
Dr. Mehmet Oz – Bio & Career
| Category | Details |
|---|---|
| Full Name | Mehmet Cengiz Oz |
| Date of Birth | June 11, 1960 |
| Age | 65 |
| Birthplace | Cleveland, Ohio, USA |
| Education | Harvard University (BA), University of Pennsylvania (MD, MBA) |
| Profession | Cardiothoracic surgeon, TV host, author, health administrator |
| Current Role | Administrator of Centers for Medicare & Medicaid Services (2025) |
| Known For | The Dr. Oz Show, medical commentary, political career |
| Business Links | Former investor in iHerb, supplement retailer |
| Family | Married to Lisa Oz, four children |
| Reference | Dr. Oz – Wikipedia |
Using his position as a doctor and administrator, Oz became the focal point of inquiries about whether he could benefit from the attention he received because of his previous affiliation with iHerb. The discussion got especially heated because Oz used to be an investor in iHerb, a company that sells over-the-counter folinic acid supplements. The situation is unclear because, although he promised in February to sell within 90 days of receiving government approval, he disclosed that he might keep stock until a buyout or initial public offering. Critics found the ambiguity to be a fertile ground, arguing that private interest and public service should never seem so closely related.
The controversy is remarkably similar to other celebrity-health incidents where public advice was confused with personal benefit. Gwyneth Paltrow was criticized for her Goop empire’s health claims, and Tom Brady’s TB12 supplement sales skyrocketed after he linked his regimen to longer performance. The product itself was shortened to the celebrity’s name in each instance, turning scientific subtlety into market momentum.
Scientific subtlety is crucial in the folinic acid case. For children with certain metabolic markers, particularly those with folate receptor autoantibodies, folinic acid supplementation can be remarkably effective, according to research like that conducted by Dr. Richard Frye. Although studies were small and frequently included fewer than fifty participants, improvements in speech and interaction were documented. Experts emphasize that the treatment is not a panacea, is not universal, and could be harmful if not used with precision testing. UChicago’s Dr. Karam Radwan noted that abuse could lead to agitation or hostility, serving as a reminder of how quickly hype can overtake facts.
But optimism is difficult to stifle. Families with autistic children, particularly those who are underserved by traditional therapies, find the concept of a vitamin-related solution especially helpful. In the last ten years, parents have experimented with everything from gluten-free diets to stem cell infusions, frequently spending thousands of dollars with little discernible result. The FDA’s cautious approval of leucovorin as a prescription option carried symbolic weight in light of this. The fact that research was addressing a critical need, even if slowly, felt like confirmation.
The consumer market reacted nearly immediately. According to reports, folinic acid supplements on iHerb and comparable websites sold out within hours of the announcement. The way that trust in personalities can spark demand more quickly than science can is exemplified by this phenomenon. The rush was reminiscent of the times when Oprah highlighted a new book or Elon Musk praised Dogecoin, both of which resulted in instantaneous economic spikes. This time, the stakes were higher—not financial speculation, but parents holding onto the hope that their kids would grow up.
Authorities tried to make very distinct distinctions. Only prescription leucovorin was approved by the FDA, not the supplement forms, the Department of Health and Human Services explained. The distinction between prescription and over-the-counter folinic acid is frequently hazy in the public’s mind, they stressed. Memes, accusations, and exultant statements that Dr. Oz was about to make money, however, had already saturated social media by that point.
It had strong optics. The scene, which included a well-known physician, a president with a reputation for making dubious health claims, and an FDA approval that was revealed during a heated press conference, evoked both skepticism and optimism. The situation was further clouded by Trump’s unsubstantiated remarks regarding Tylenol and autism, which combined political theater with a potentially effective treatment. It brought to light how public health announcements can be turned into political arenas where spectacle threatens to overshadow the science.
What this reveals about contemporary health communication is especially novel. In addition to being about a supplement, the history of folinic acid also explores the dissemination of information in a society driven by celebrity, mistrust, and urgency. Oz was accused of profiteering by organic chemists and policy consultants on X, while traditional outlets cautiously covered the early science. Meanwhile, supplement websites were overrun by parents, who made decisions influenced more by the emotional impact of a press conference than by peer-reviewed journals.
The instance captures the complexities of Dr. Oz’s career. His ability to translate complex science into easily understood advice, sometimes at the expense of accuracy, has made him an extremely effective communicator. From surgeon to talk show host to Senate candidate to health administrator, his career path has made him extremely adaptable but also a target of criticism. He was once again at the intersection of medicine, business, and controversy because of his affiliation with folinic acid, regardless of any financial connections.
